Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Blue Trust Inc.

Blue Trust Inc. boosted its position in Royalty Pharma plc (NASDAQ:RPRX) by 31.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,579 shares of the biopharmaceutical company’s stock after acquiring an additional 376 shares during the quarter. Blue Trust Inc.’s holdings in Royalty Pharma were worth $45,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. boosted its holdings in Royalty Pharma by 5.0% in the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company’s stock valued at $40,705,000 after acquiring an additional 70,130 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Royalty Pharma by 171.1% in the third quarter. Van ECK Associates Corp now owns 101,500 shares of the biopharmaceutical company’s stock valued at $2,777,000 after acquiring an additional 64,057 shares during the last quarter. Summit Global Investments purchased a new stake in Royalty Pharma during the third quarter worth approximately $735,000. Pallas Capital Advisors LLC acquired a new stake in shares of Royalty Pharma in the fourth quarter worth $2,355,000. Finally, Two Sigma Advisers LP raised its stake in shares of Royalty Pharma by 44.7% in the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock valued at $85,809,000 after acquiring an additional 936,900 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on RPRX shares. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. Finally, Citigroup dropped their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, October 25th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $41.67.

Royalty Pharma Price Performance

Shares of RPRX stock opened at $31.73 on Monday. The company has a market capitalization of $18.69 billion, a PE ratio of 16.44 and a beta of 0.49. The firm has a fifty day simple moving average of $27.83 and a 200-day simple moving average of $27.64. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $32.21.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be issued a dividend of $0.22 per share. The ex-dividend date is Friday, February 21st. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 2.77%. Royalty Pharma’s payout ratio is currently 43.52%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.